Prediction of response to vemurafenib in BRAF V600E mutant cancers based on a network approach

被引：0
|
作者：
Falcone, R. [1 ]
Paci, P. [2 ]
Verrienti, A. [1 ]
Fiscon, G. [2 ]
Sponziello, M. [1 ]
Conte, F. [2 ]
Pecce, V. [1 ]
Rosignolo, F. [1 ]
Grani, G. [1 ]
Lamartina, L. [1 ]
Ramundo, V. [1 ]
Durante, C. [1 ]
Farina, L. [3 ]
Filetti, S. [1 ]
机构：
[1] Sapienza Univ Rome, Policlin Umberto 1, Dipartimento Med Interna & Specialita Med, Rome, Italy
[2] CNR, Inst Syst Anal & Comp Sci Antonio Ruberti, Rome, Italy
[3] Sapienza Univ Rome, Dept Stat Sci, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1887P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Vemurafenib FDG-PET preclinical imaging outcomes across BRAF V600E mutant and resistant tumors
    Baudy, Andreas R.
    Dogan, Taner
    Flores, Judith E.
    Hoeflich, Klaus P.
    Su, Fei
    van Bruggen, Nicholas
    Williams, Simon P.
    CANCER RESEARCH, 2012, 72
  • [22] Management of V600E and V600K BRAF-Mutant Melanoma
    Alexandra M. Haugh
    Douglas B. Johnson
    Current Treatment Options in Oncology, 2019, 20
  • [23] Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
    Goodall, Megan L.
    Wang, Tong
    Martin, Katie R.
    Kortus, Matthew G.
    Kauffman, Audra L.
    Trent, Jeffrey M.
    Gately, Stephen
    MacKeigan, Jeffrey P.
    AUTOPHAGY, 2014, 10 (06) : 1120 - 1136
  • [24] Management of V600E and V600K BRAF-Mutant Melanoma
    Haugh, Alexandra M.
    Johnson, Douglas B.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (11)
  • [25] Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
    Matthias Lang
    Thomas Longerich
    Chrysanthi Anamaterou
    Thyroid Research, 16
  • [26] Vemurafenib in Patients With BRAF V600E Mutation-Positive Advanced Melanoma
    Ravnan, Marcus C.
    Matalka, Mazen S.
    CLINICAL THERAPEUTICS, 2012, 34 (07) : 1474 - 1486
  • [27] Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
    Lang, Matthias
    Longerich, Thomas
    Anamaterou, Chrysanthi
    THYROID RESEARCH, 2023, 16 (01)
  • [28] Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
    Marks, Asher M.
    Bindra, Ranjit S.
    DiLuna, Michael L.
    Huttner, Anita
    Jairam, Vikram
    Kahle, Kristopher T.
    Kieran, Mark W.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [29] BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
    Barras, David
    Missiaglia, Edoardo
    Wirapati, Pratyaksha
    Sieber, Oliver M.
    Jorissen, Robert N.
    Love, Chris
    Molloy, Peter L.
    Jones, Ian T.
    McLaughlin, Stephen
    Gibbs, Peter
    Guinney, Justin
    Simon, Iris M.
    Roth, Arnaud D.
    Bosman, Fred T.
    Tejpar, Sabine
    Delorenzi, Mauro
    CLINICAL CANCER RESEARCH, 2017, 23 (01) : 104 - 115
  • [30] Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
    Fedorenko, Inna V.
    Paraiso, Kim H. T.
    Smalley, Keiran S. M.
    BIOCHEMICAL PHARMACOLOGY, 2011, 82 (03) : 201 - 209
12345